Prakt. lékáren. 2017; 13(1): 18-20 | DOI: 10.36290/lek.2017.002

Omeprazole suspension 2 mg/ml – a new dosage form for pediatric use

Markéta Petrželová1, Petr Horák1, Anežka Hordějčuková1, Ludmila Matysová2
1Nemocniční lékárna, Fakultní nemocnice v Motole, Praha
2Katedra analytické chemie, Farmaceutická fakulta v Hradci Králové, Univerzita Karlova

The article discuss the possibilities of extemporaneous preparation of omeprazole suspension in pediatric practice. The suspensions

are individually prepared viscous, flavored suspension for oral use and unflavored suspensions for administration to the

gastric feeding tube.

This article summarizes the resulting stability data of products with omeprazole.

Keywords: omeprazole suspension, extemporaneous preparation, pediatrics, gastroesophageal reflux

Published: March 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Petrželová M, Horák P, Hordějčuková A, Matysová L. Omeprazole suspension 2 mg/ml – a new dosage form for pediatric use. Praktické lékárenství. 2017;13(1):18-20. doi: 10.36290/lek.2017.002.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Český lékopis 2009. 1. vydání ed. Praha: Grada Publishing; 2009.
    2. Martindale: The komplete drug reference, 36. edition, Pharmaceutical Press; 2009; p. 1753.
    3. Trissel L. A. Stability of compounded formulations. 5th ed. Washington: American Pharmacicts Association 2012; p. 418-420.
    4. Suchopár J, et al. Remedia Compendium, 4. Vydání, Panax Co, spol. s r. o.; 2009; s. 6.
    5. Burnett JE, Balkin ER. Stability and viskosity of a flavored omeprazole oral suspension for pediatric use. Am J Health-Syst Pharm. 2006; 63: 2240-2247. Go to original source... Go to PubMed...
    6. http://www.infant-acid-reflux-solutions.com/marci-kids-dosing-calculator.html (cit. 2016-08-30).
    7. BNF for Children 2012-2013. London: Pharmaceutical Press 2012.
    8. FDA: Highlights of prescribing information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021849s010021636s016lbl.pdf [cit. 2016-08-30].
    9. Highlights of prescribing information, Zegerid(R) Powder for Oral Suspension for Santaurus, Inc.
    10. Quercia RA, Fan Ch, Liu X, Chow MSS. Stability of omeprazole in an extemporaneously prepared oral liquid. Am J Health-Syst Pharm. 1997; 54: 1833-1836. Go to original source... Go to PubMed...
    11. Mignini I, Stancari A, Bersani G, Maselli S, Guarguaglini AM, De Simone S, Corvaglia LT, Puggioli C. Omeprazole oral suspension for pediatric patiens: Preparation and use of a new galenic formula in hospitál pharmacy. ESCP-GSASA Symposium, Geneva, 3-6 November 2009.
    12. Johnson CE, Cober MP, Ludwig JL. Stability of partial doses of omeprazole - sodium bicarbonate oral suspension. The Annals of Pharmacotherapy. 2007; 41: 1954-1961. Go to original source... Go to PubMed...
    13. PA Whaley, BS; MA VondricII, MS, PMP; B. Sorenson, CAPM Stability of Omeprazole in SyrSpend SF Alka (Reconstituted).International Journal of Pharmaceutical Compounding. 2012; 16: 164-166. Go to PubMed...

    Return to the content


    Pharmacy for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.